XZB-0004 is under clinical development by SignalChem Lifesciences and currently in Phase I for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase I drugs for Coronavirus Disease 2019 (COVID-19) have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how XZB-0004’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

XZB-0004 overview

SLC-391 is under development for the treatment of solid tumors, non-small cell lung cancer (NSCLC), squamous non-small cell lung cancer, metastatic transitional (urothelial) tract cancer, metastatic melanoma, acute myelocytic leukemia (AML), colorectal cancer,  relapsed and refractory acute myeloid leukemia and myelodysplastic syndrome. The drug candidate is a small molecule that acts by targeting AXL kinase. It is developed based on the KineCore technology. It is administered through oral route. The drug candidate was also under development for colon carcinoma and ovarian cancer.
SLC-391 was under development for the treatment of chronic myelocytic leukemia (CML), ovarian cancer, colon carcinoma and COVID-19.

SignalChem Lifesciences overview

SignalChem Lifesciences (SLC) is a biotechnology company that discovers and develops novel therapies for oncology. The company’s pipeline products include SLC-391 which targets non-small cell lung cancer, myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML); SLC-0111 treats pancreatic ductal adenocarcinoma (PDAC); SLC-500, SLC-600, SLC-700 for solid tumors. Its portfolio comprises cutting-edge, small molecule therapies specifically designed to target crucial proteins responsible for cancer initiation, progression and treatment resistance with unparalleled precision. The company works in collaboration with pharmaceutical companies, contract research organizations and academics to develop its products. SLC is headquartered in Richmond, British Columbia, Canada.

For a complete picture of XZB-0004’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.